Cefuroxime axetil

Area of Science:

• Pharmacology
• Infectious Diseases
• Microbiology

Background:

• Cefuroxime axetil is an orally administered prodrug of cefuroxime.
• Upon absorption, it is rapidly converted to the active form, cefuroxime.
• This formulation broadens the therapeutic options for cefuroxime administration.

Purpose of the Study:

• To evaluate the in vitro antibacterial spectrum of cefuroxime axetil.
• To assess its clinical efficacy in treating common bacterial infections.
• To compare its effectiveness against established antibiotic therapies.

Main Methods:

• In vitro susceptibility testing against various bacterial pathogens.
• Clinical trials comparing cefuroxime axetil with ampicillin, amoxicillin, amoxicillin/clavulanic acid, penicillin V, and cefaclor.
• Evaluation of treatment outcomes for uncomplicated urinary tract infections, acute otitis media, upper respiratory infections, skin and soft tissue infections, and gonorrhea.

Main Results:

• Cefuroxime axetil demonstrates in vitro activity against many gram-positive and some gram-negative organisms.
• Its beta-lactamase stability is advantageous against resistant strains of Haemophilus influenzae, Branhamella catarrhalis, and Staphylococcus aureus.
• Clinical studies indicate comparable efficacy to ampicillin, amoxicillin, amoxicillin/clavulanic acid, penicillin V, and cefaclor for specified infections.

Conclusions:

• Cefuroxime axetil is an effective oral antibiotic with a broad spectrum of activity.
• Its beta-lactamase stability enhances its utility against resistant bacterial strains.
• It represents a viable therapeutic option for various common bacterial infections, demonstrating comparable efficacy to other standard treatments.